Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy最新文献

{"title":"Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients.","authors":"Carlos Alexandre Ferreira de Oliveira, Livia Maria Borges Amaral, José Pedro Cassemiro Micheleto, Karin Araujo Melo, Mateus de Medeiros Rijo, Pedro Gustavo Barbosa Lira, Emiliano de Oliveira Barreto, Juliane Pereira da Silva, Antônio Filipe Pereira Caetano, Juliana Célia de Farias Santos, Michelle Jacintha Cavalcante Oliveira","doi":"10.1111/1744-9987.14237","DOIUrl":"10.1111/1744-9987.14237","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes, obesity, and CKD collectively impact musculoskeletal health and increase the risk of severe coronavirus disease 2019 (COVID-19) outcomes.</p><p><strong>Methods: </strong>This cross-sectional study included 32 dialysis patients, categorized based on their COVID-19 status. Laboratory assessments included inflammatory markers (IL-1β, IL-6, IL-8, and TNF-α). Sarcopenia risk was evaluated using the strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire, bioimpedance analysis, and static muscle strength testing.</p><p><strong>Results: </strong>No significant differences were observed between groups in laboratory values, sarcopenia risk, or inflammatory markers. Body composition, SARC-F scores, and static muscle strength were comparable across both groups, except for elevated parathyroid hormone (PTH) levels in Group A (p = 0.008).</p><p><strong>Conclusion: </strong>The lack of association between the inflammatory response and sarcopenia risk may be attributed to the existing inflammatory status of this population, given the coexistence of diabetes, CKD, and obesity. Notably, all studied laboratory variables showed no significant differences, except for the higher PTH levels.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"705-712"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.","authors":"Jing Li, Binghai Huang, Qifang Lao, Longtao Zou, Kaiqing Xie","doi":"10.1111/1744-9987.14240","DOIUrl":"10.1111/1744-9987.14240","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the clinical efficacy and safety of plasma exchange (PE) in the treatment of glucocorticoid-insensitive patients with serum anti-N-methyl-d-aspartate (anti-NMDA) receptor antibody-negative and serum anti-NMDA receptor antibody-positive encephalitis.</p><p><strong>Methods: </strong>The clinical data of 20 patients with anti-NMDA receptor antibody encephalitis treated between January 2015 and December 2022 were collected. The general information, clinical symptoms, auxiliary examination, treatment (hormone, PE, etc.), adverse reactions, clinical efficacy, and other related data were retrospectively compared and analyzed.</p><p><strong>Results: </strong>A total of 8 cases had adverse reactions (9.76%, 8/82), including 4 cases (4.88%, 4/82) of allergy and 2 cases (2.44%,2/82) of thrombocytopenia. In patients with anti-NMDA receptor antibody encephalitis who were not sensitive to glucocorticoids, the effective rate of PE was 80.0% (p = 0.0005).</p><p><strong>Conclusion: </strong>PE combined with glucocorticoid is more effective than glucocorticoid alone in the treatment of anti-NMDA receptor antibody encephalitis patients with positive or negative anti-NMDA receptor antibodies. Most adverse reactions were mild and easy to manage. It does not cause obvious blood cell loss. PE is a safe and acceptable treatment. However, our study has limitations, and due to the small number of people and the fact that plasmapheresis was performed after glucocorticoid therapy, further prospective clinical studies are warranted.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"698-704"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-Zero Definition, Treated-Only Denominator, and Case Definition Limit the Interpretation of Timing.","authors":"Emre Cankaya","doi":"10.1002/1744-9987.70198","DOIUrl":"10.1002/1744-9987.70198","url":null,"abstract":"","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"792-793"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148552007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of plasmapheresis and hemoperfusion in COVID-19 survivors: A six-month follow-up analysis after hospital discharge.","authors":"Soroush Dianaty, Farshid Gholami, Hamid Reza Gholamrezaie, Abasat Mirzaei","doi":"10.1111/1744-9987.14235","DOIUrl":"10.1111/1744-9987.14235","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate the short- and long-term clinical and financial outcomes of apheresis in COVID-19 survivors after hospital discharge.</p><p><strong>Methods: </strong>Intensive care unit-discharged patients were followed for 6 months. Vital signs, laboratory markers, quality of life, and direct medical costs were analyzed to calculate incremental cost-effectiveness ratios (ICER) and to plot cost-effectiveness planes and acceptability curves.</p><p><strong>Results: </strong>A total of 68 patients (45 control, 18 plasmapheresis, and 5 hemoperfusion) were included. ICERs for plasmapheresis and hemoperfusion patients at discharge were $867.58 and $198.89 per quality-adjusted life years (QALY) gained, respectively. Respiration and blood pressure improved significantly at discharge. The improvements in oxygenation markers for plasmapheresis and hemoperfusion groups were lower than controls (8.56 ± 10.31 and 11.75 ± 16.88 vs. 11.37 ± 7.28 percent for SpO₂, 11.15 ± 21.15 and 11.05 ± 24.95 vs. 16.03 ± 5.61 mm Hg for PaO₂, respectively) However, the respiratory rate improvements corresponded to ICERs of $1034.77 and $269.94 for plasmapheresis and hemoperfusion, respectively. The ICERs for increasing mean arterial pressure were $24.83 and $30.94 per mm Hg, and plasmapheresis was more cost-effective than hemoperfusion in increasing serum calcium levels ($1649.35 per mg/dL). At 1-month post-discharge, both treatments showed worse outcomes compared to controls. At 6 months, the plasmapheresis ICER ($1884.95) exceeded the willingness-to-pay threshold. The ICER for plasmapheresis at 6 months was $112.83 per rehospitalization day avoided, while hemoperfusion remained less effective than controls.</p><p><strong>Conclusion: </strong>While plasmapheresis and hemoperfusion improved some clinical outcomes, their high costs and limited long-term cost-effectiveness suggest that these interventions may not be economically justified for treating COVID-19 patients. Careful evaluation is needed when considering their use in clinical practice.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"769-781"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of gut microbiota in incident and prevalent peritoneal dialysis patients with peritoneal fibrosis, correlations with peritoneal equilibration test data in the peritoneal fibrosis cohort.","authors":"Jiangqing Fan, Lingyun Wang, Ting Yang, Jing Liu, Weihong Ge, Jizhong Shen, Lulu Wang","doi":"10.1111/1744-9987.14226","DOIUrl":"10.1111/1744-9987.14226","url":null,"abstract":"<p><strong>Introduction: </strong>The connection between peritoneal function and gut microbiota in peritoneal fibrosis (PF) patients remains uncertain.</p><p><strong>Methods: </strong>Peritoneal equilibration test (PET) was employed to evaluate peritoneal function in patients with peritoneal fibrosis (PF). 16S rRNA sequencing was used to analyze the gut flora in incident peritoneal dialysis (PD) and PF groups, identifying differential microbial communities. Spearman's correlation analysis, conducted using SPSS 26.0, was employed to explore the microbial associations with PF.</p><p><strong>Results: </strong>In the PF group, the PET showed a 4-h dialysate-to-plasma creatinine ratio (D/PCr) ratio of 0.62 ± 1.01 and a 4-h ultrafiltration (UF) volume of 41.73 ± 76.71 mL with a 2.5% glucose dwell. The alpha diversity between the PD and PF groups did not exhibit a significant difference. The PD and PF groups were predominantly composed of Firmicutes, Tenericutes, and Ignavibacteriae. Linear discriminant analysis effect size (LEfse) analysis indicates that the Firmicutes, Lactobacillales, and Bacilli were significantly enriched in the PD group, whereas Lachnospiraceae, Phenylobacterium, and Caulobacteraceae were enriched among the PF group. The functional prediction of gut microbiota genes revealed variations in metabolic pathways related to lipid transport, energy metabolism, and post-translational protein modifications between the two cohorts. In the PF group, Ignavibacteriae and Bdellovibrio correlated positively with the 4-h D/PCr ratio (p <0.05), while Prevotella negatively correlated with the 4-h UF from 2.5% glucose dwell (p <0.05).</p><p><strong>Conclusion: </strong>The intestinal microbiota of patients newly initiated on peritoneal dialysis significantly differs from that of those with long-term peritoneal dialysis complicated by peritoneal fibrosis, with the latter's peritoneal function potentially linked to Prevotella, Ignavibacteriae, and Bdellovibrio.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"658-668"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NLRP3 Inflammasome Activation and Atherogenic Lipid Profile in Hemodialysis Patients.","authors":"Mohammed N Abdelaziz, Nehal Elshabrawy, Ahmed Almenshawy, Karim A Elsodany, Hager G Elkasabi, Ahmed A Hammad, Hana H Attia, Khaled Mokhtar, Radwa ElSayed, Emad Samaan","doi":"10.1002/1744-9987.70158","DOIUrl":"10.1002/1744-9987.70158","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;End-stage renal disease (ESRD) patients who undergo hemodialysis treatment experience accelerated atherosclerosis development, which results from two main causes: atherogenic dyslipidemia and chronic inflammation. The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which serves as an essential innate immunity regulator, has links to cardiovascular disease development; yet researchers have not effectively studied its connection to atherogenic lipid profiles among dialysis patients. This study examined the association between NLRP3 inflammasome levels and the atherogenic index of plasma (AIP) in hemodialysis patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study at Mansoura University Hospital focused on adults with ESRD or chronic kidney disease (CKD) stage 5 undergoing hemodialysis. Participants over 18 years attended three sessions weekly, with exclusions for pregnant individuals, previous kidney transplant patients, those on different dialysis methods, active infection sufferers, and recent medication users. The research measured serum NLRP3 inflammasome levels, hematological parameters, and lipid profiles, calculating the AIP. Sequential multivariable linear regression sensitivity models with bootstrapping examined the association between NLRP3 levels and the atherogenic index, while ensuring accuracy by checking for multicollinearity using variance inflation factors (VIFs).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 44 hemodialysis patients (median age 49 years, 57% female, 75% hypertensive), NLRP3 inflammasome levels showed wide variation (median 168.7 ng/L, IQR: 76.6-404.6), alongside atherogenic dyslipidemia marked by elevated indices: AIP 0.04 (-0.14 to 0.34), Castelli I 3.42 (3.01-4.61), remnant cholesterol 0.54 mmol/L (0.39-0.84), and atherogenic coefficient 2.42 (2.01-3.61), with lipids including TG 1.18 mmol/L (0.85-1.82), HDL-C 1.08 (0.92-1.21), LDL-C 2.14 (1.62-2.89). Sequential multivariable linear regression sensitivity models with bootstrapping revealed NLRP3 levels significantly associated with AIP (unadjusted B = 0.001, p &lt; 0.001; age and gender-adjusted B = 0.001, p = 0.002; adjusted for smoking/uric acid/LDL-C/SBP B = 0.001, p = 0.016), robust via bootstrapping (2000 iterations, VIF &lt; 1.5, no multicollinearity). Dialysis adequacy was good (K &lt;sub&gt;t&lt;/sub&gt;/V 1.48, urea reduction ratio [URR] 66.3%), with hypertensive nephropathy predominant (38.6%); complications like intradialytic hypotension (38.6%) were common. Metabolic syndrome affected 50%. Findings suggest NLRP3 inflammasome levels are associated with atherogenic dyslipidemia in maintenance hemodialysis patients. Further longitudinal studies are needed to determine causal relationships and whether NLRP3 inhibition could reduce cardiovascular risk in this population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In this exploratory single-center study, circulating NLRP3 levels were associated with AIP-defined atherogenic lipid ","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"782-789"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina.","authors":"Daniela Wojtowicz, Gustavo Laham, Mariano Forrester, Elisa Del Valle, Adriana Peñalba, Graciela Filannino, Andrea Sammartino, Cecilia Mengarelli, Guillermo Rosa-Diez, Armando Luis Negri","doi":"10.1111/1744-9987.14230","DOIUrl":"10.1111/1744-9987.14230","url":null,"abstract":"<p><strong>Introduction: </strong>Secondary hyperparathyroidism (sHPT) is a common complication in patients with chronic kidney disease (CKD). Recently, etelcalcetide (EC), an intravenous calcimimetic, has been introduced as a treatment. We evaluated the efficacy of EC in treating sHPT.</p><p><strong>Methods: </strong>We conducted a multicenter, observational, retrospective study involving hemodialysis patients with sHPT, treated for at least 3 months with EC. We analyzed baseline and follow-up values of intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), and alkaline phosphatase (ALP). Age, sex, time on dialysis, dialysate calcium concentration, and use of active vitamin D and phosphate binders were also recorded. Patients were divided into those receiving EC as de novo or after at least 3 months of cinacalcet treatment, and according to sHPT severity: PTH <1000 and >1000 pg/mL.</p><p><strong>Results: </strong>The study included 196 patients. Mean age was 52 ± 15 years; 52.3% were male. Median time on hemodialysis was 46.5 (20-72) months. Significant reductions were observed in baseline iPTH (1053 pg/mL), Ca (8.7 mg/dL), and P (5.7 mg/dL) over 2 years (p < 0.0001), while ALP levels remained stable. iPTH reduction >30% was achieved in 37.5%, 64%, 66.7%, and 62.5% of patients at 3, 6, 12, and 24 months, respectively. EC was administered as initial treatment in 53% of patients, while 47% were switched from cinacalcet. Significantly iPTH reduction was observed in both groups. Greater reductions were noted in patients with initial PTH >1000 pg/mL (p = 0.009). Two patients discontinued due to severe hypocalcemia.</p><p><strong>Conclusions: </strong>EC effectively lowered iPTH and P levels, with a sustained effect over 2 years.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"669-675"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effect of therapeutic plasma exchange on serum cytokine levels in pediatric intensive care unit.","authors":"Selen Ceren Cakmak, Hazal Ceren Tugrul, Dilan Akgun Unlu, Rasit Alkan Albayrak, Gurkan Atay, Seher Erdogan, Betul Sozeri","doi":"10.1111/1744-9987.14246","DOIUrl":"10.1111/1744-9987.14246","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic plasma exchange (TPE) is crucial for saving lives when used appropriately. This study aimed to assess TPE's impact on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) protein and IL-6 levels in critically ill pediatric patients.</p><p><strong>Methods: </strong>Conducted between May 2022 and December 2022, the study observed pediatric intensive care unit (PICU) patients undergoing TPE, recording demographics, lab results, TWEAK, and IL-6 levels pre- and post-procedure.</p><p><strong>Results: </strong>Of 41 patients, 53.7% were male, 51.2% had underlying conditions, and 39% showed sepsis symptoms. IL-6 levels significantly rose post-TPE (p: 0.006), while TWEAK protein levels dropped (p: 0.030). Positive correlations were found between interleukin-6 (IL-6) pre-TPE and ventilation duration, ferritin levels (p <0.05), and TWEAK pre-TPE and organ failure indicators, D-Dimer levels (p <0.05). Prognosis showed no significant difference in IL-6/TWEAK levels (p >0.05).</p><p><strong>Conclusion: </strong>Serum IL-6 and TWEAK can indicate disease severity and inflammation level, but may not predict prognosis accurately.</p><p><strong>Clinical trial registration: </strong>Our study has clinical study registration number B.10.1.TKH.4.34.H.GP.0.01/154 of the University of Health Sciences Ümraniye Training and Research Hospital.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"749-759"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tryptophan-immunoadsorption plasmapheresis regulates polymorphonuclear-myeloid-derived suppressor cells and pro-inflammatory cytokines.","authors":"Hanae Wakabayashi, Noriyuki Hattori, Akiyuki Uzawa, Michihiro Ito, Hiroko Hasegawa, Naoya Mimura, Maulana Empitu, Masashi Aizawa, Satoshi Kuwabara, Katsuhiko Asanuma, Shigeto Oda","doi":"10.1111/1744-9987.14228","DOIUrl":"10.1111/1744-9987.14228","url":null,"abstract":"<p><strong>Introduction: </strong>Immunoadsorption plasmapheresis (IA) has been reported to have immunoregulatory effects, in addition to the removal of autoantibodies. This study aimed to investigate the effects of IA on the proportion of myeloid-derived suppressor cells (MDSCs) that potentially suppress autoimmune responses and regulate immunity.</p><p><strong>Methods: </strong>The study included 21 patients with autoimmune neurological diseases and 8 healthy participants. We measured polymorphonuclear (PMN)-MDSCs (CD14^-CD11b⁺CD33⁺) and inflammation-related mediators before and after a single session of tryptophan-IA. We also investigated whether an increase in PMN-MDSCs after initial IA was a predictor of clinical efficacy in nine patients with myasthenia gravis based on the Quantitative Myasthenia Gravis score.</p><p><strong>Results: </strong>For a total of 36 times of IA procedures, the number of PMN-MDSCs significantly increased after IA. Interleukin-10, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1β levels showed significant increases after IA. Despite similar severity at admission, the Quantitative Myasthenia Gravis scores at discharge were significantly lower in the group in which IA increased PMN-MDSCs to a level of 20% of peripheral blood mononuclear cells or more.</p><p><strong>Conclusion: </strong>Tryptophan-IA regulates PMN-MDSCs and pro-inflammatory cytokines, possibly leading to suppression of autoimmune responses and tissue damage in neuroimmunological disorders.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"649-657"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic plasma exchange without anticoagulation: Single-center experience.","authors":"Eduardo Zúñiga-Rodríguez, Danna Peña, Juliana Mantilla, Juan Camilo Castellanos-De La Hoz, Maria Patricia Carvajal-Abril, Isabel Cristina Saravia Bermeo, Alejandra Molano-Triviño","doi":"10.1111/1744-9987.14227","DOIUrl":"10.1111/1744-9987.14227","url":null,"abstract":"<p><strong>Background: </strong>Membrane therapeutic plasma exchange (mTPE) is indicated for treating autoimmune, neurological, hematological, and renal diseases. Few studies have assessed the effectiveness and safety of this technique, especially when no anticoagulants are added. This study evaluated the outcomes of mTPE without anticoagulation at a single center.</p><p><strong>Methods: </strong>Based on registry data, this retrospective cohort study included adult patients treated with mTPE without anticoagulants for different indications.</p><p><strong>Results: </strong>From October 2021 to October 2022, 46 patients received 385 mTPE treatments. The primary diagnosis leading to the intervention was humoral rejection of the kidney transplant (59.2%). Most procedures (62.1%) were performed in the inpatient department. The complication rate was 1.3%, with 2.1% of patients experiencing device coagulation. Only five patients experienced mild adverse events. There were no cases of mortality.</p><p><strong>Conclusions: </strong>When indicated, mTPE without anticoagulation is a safe hospital technique. Protocols are needed to guide the use and monitoring of this therapy.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"641-648"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}